Form 4: Rhythm Pharmaceuticals Director Converts Restricted Stock Units to Common Shares

David W.J. McGirr, a Director at Rhythm Pharmaceuticals, Inc., acquired 4,000 shares of common stock through the vesting and conversion of Restricted Stock Units.

Summary

• David W.J. McGirr, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), acquired 4,000 shares of the company's common stock.
• The acquisition occurred on June 18, 2025, through the vesting and conversion of Restricted Stock Units (RSUs).
• Each RSU represented a contingent right to receive one share of common stock, and the 4,000 RSUs fully vested on the transaction date.
• The conversion price for these RSUs was $0.00.
• Following this transaction, Mr. McGirr directly beneficially owns 7,000 shares of Rhythm Pharmaceuticals, Inc. common stock.
• No derivative securities (RSUs) are beneficially owned by Mr. McGirr after this transaction.

Sentiment

Score: 7

Explanation: The transaction is a routine RSU vesting and conversion, which is a positive sign of a director's continued alignment with shareholder interests, but it does not indicate new strategic developments or significant financial performance changes.

Positives

• The transaction demonstrates a director's continued beneficial ownership in Rhythm Pharmaceuticals, Inc., aligning their interests with shareholders.
• The conversion of Restricted Stock Units into common stock indicates the fulfillment of a pre-scheduled compensation agreement.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The transaction indicates a director's continued direct ownership in the company, which can be viewed positively as it aligns management interests with shareholder value.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Ownership, Stock Acquisition